Long term prognosis in patients with pulmonary hypertension undergoing catheter ablation for supraventricular tachycardia

Hiroyuki Kamada1,4, Junji Kaneyama2,4, Yuko Y. Inoue1*, Takashi Noda1, Nobuhiko Ueda1, Kenzaburo Nakajima1, Tsukasa Kamakura1, Mitsuru Wada1, Kohei Ishibashi3, Kenichiro Yamagata1, Koji Miyamoto1, Tatsuo Aoki1, Takeshi Ogo1, Satoshi Nagase1, Takeshi Aiba2, Kazuhiro Satomi3 & Kengo Kusano1

Various forms of supraventricular tachycardia (SVT) occur in patients with severe pulmonary hypertension (PH). Despite the high efficacy of radiofrequency catheter ablation (RFCA) for SVT, insufficient data exist regarding patients with PH. Thirty SVTs in 23 PH patients (age 47 [35–60] years; mean pulmonary artery pressure 44 [32–50] mmHg) were analyzed. Procedural success rate, short- and long-term clinical outcomes, were evaluated during a median follow-up of 5.1 years. Single-procedure success rate was 83%; 94% (17/18) in typical atrial flutter, 73% (8/11) in atrial tachycardia (AT), and 100% (1/1) in atrioventricular nodal reentrant tachycardia. Antiarrhythmic drugs, serum brain natriuretic peptide levels and number of hospitalizations significantly decreased after RFCA than that before (p = 0.002, 0.04, and 0.002, respectively). Four patients had several procedures. After last RFCA, 12 patients had SVT and 8 patients died. Kaplan–Meier curves showed that patients with SVT after the last RFCA had a lower survival rate compared to those without (p = 0.0297). Multivariate analysis identified any SVT after the last RFCA as significant risk factor of mortality (hazard ratio: 9.31; p = 0.016). RFCA for SVT in patients with PH is feasible and effective in the short-term, but SVT is common during long-term follow-up and associated with lower survival.

Pulmonary hypertension (PH) is a progressive disease characterized by vascular proliferation and remodeling in the pulmonary vasculature. In recent years, various treatments have been introduced that have improved the prognosis of patients with PH1,2. Despite these therapies, however, patients with PH—including those resistant to therapies—still have a high mortality rate due to right ventricular failure3,4.

Supraventricular tachycardia (SVT) is an increasingly common clinical problem in patients with PH, and various forms of SVT can occur in these patients. Remodeling of the right atrium in response to longstanding pressure- and volume-overload appears to generate an underlying arrhythmogenic substrate5,6. Recent studies suggest that SVT is an independent prognostic factor in patients with PH7,8. Thus, from a prognostic perspective it may be worthwhile to maintain a stable sinus rhythm. However, antiarrhythmic drug (AAD) therapy may not be a feasible option because of their negative inotropic properties and interaction with therapeutic drugs for PH9.

Despite the high efficacy of radiofrequency catheter ablation (RFCA) to treat SVT in healthy subjects, limited data are available regarding the efficacy and safety of RFCA for patients with PH.

The current study presents short- and long-term data from a single-center series of patients with PH undergoing RFCA for SVT and explores the influence of procedural and clinical variables on clinical outcomes.

Methods
Eligibility criteria. This was a retrospective single study based on a tertiary center. We enrolled 23 consecutive patients with pre-capillary PH undergoing RFCA for a history of sustained and/or recurrent SVT at the National Cerebral and Cardiovascular Center between January 1998 and October 2019. SVT included atrial
flutter (AFL), atrial tachycardia (AT), and atrioventricular nodal reentrant tachycardia (AVNRT); no patients with SVT from left atrium or atrial fibrillation (AF) underwent RFCA in this study. We excluded patients with PH secondary to left-sided heart disease (European Society of Cardiology [ESC]/European Respiratory Society [ERS] Clinical Group 2; pulmonary artery wedge pressure > 15 mmHg; n = 8). PH was defined as mean pulmonary arterial pressure ≥ 25 mmHg at rest, before electrophysiological study (EPS)10. All data on pulmonary pressures were obtained from right heart catheterization except for one patient with PH, due to inoperable Eisenmenger syndrome. Data were extracted from medical records and procedure notes. The study was approved by the National Cerebral and Cardiovascular Center ethics review board (M26-148), and we applied Opt-out method to obtain informed consent. The study complied with the Declaration of Helsinki.

Cardiac electrophysiological study and catheter ablation. If SVT was not present at the beginning of the EPS, induction of SVT was attempted with programmed atrial stimulation from high in the right atrium or coronary sinus, as detailed in the Data Supplement. A three-dimensional (3D) activation sequence map of the right atrium during SVT was constructed in 16 patients (70%). Focal AT (FAT), intra-atrial reentrant tachycardia (IART), and AVNRT were ablated at the earliest lesion, critical isthmus, and slow pathway, respectively. Procedure time was defined as the duration from the puncture to removal of the sheaths.

Acute procedure outcome measures. Targeted SVT included clinical and non-clinical SVT, except AF, occurring during EPS and RFCA. Acute success or failure were defined as termination of an SVT circuit during application of radiofrequency energy, or no subsequent inducibility by programmed stimulation. Complete success of RFCA was defined as a procedure in which all targeted SVT circuits were terminated, and partial success was defined as a procedure in which one or more targeted SVT circuits were acutely terminated, but not all targeted SVT circuits were ablated, or SVT was unmappable because of unmappable or non-sustained AT.

The safety outcome of RFCA was assessed by the occurrence of complications. The definition of a complication included any event that was causally related to the RFCA and occurred within 24 h of the procedure.

Short- and long-term clinical outcomes. All patients were evaluated at our center every 1–3 months using a 12-lead electrocardiogram, 24-h Holter monitor, or portable electrocardiograph when patients complained of palpitations. Patients whose symptoms recurred were evaluated immediately. SVT and complications after RFCA were confirmed by medical records and the definition of SVT was arrhythmia lasting for > 30 s.

Three measures were used to evaluate RFCA efficacy in relation to short-term outcomes, including (1) the number of AADs administered on admission and discharge following RFCA, (2) serum brain natriuretic peptide (BNP) levels one month before and after RFCA, and (3) the number of admissions associated with heart failure or arrhythmia within the 1-year period before and after RFCA.

The long-term outcome of a patient was defined as any SVT and all-cause mortality after RFCA. SVT after the RFCA procedure included the recurrence of targeted SVT and new onset of any type of SVT, including AF or another SVT from both atria not targeted during the RFCA, and were divided into long-term SVT (n = 12) and no long-term SVT group (n = 11).

Statistical analysis. Continuous data were represented as median and interquartile range, and categorical variables as number (percentage). Continuous variables were compared between two groups using non-parametric Mann–Whitney U test, and categorical data were compared using the chi-squared test or Fisher’s exact test where appropriate. According to the distribution of the data sets, the statistical differences between pre-ablation and post-ablation values were determined by two-sided paired t-test, Wilcoxon signed-rank sum test, or McNemar test. Kaplan–Meier survival curves were used to estimate the cumulative incidence of SVT and the survival of patients by the log-rank test. Univariate and multivariate Cox proportional regression analyses were performed to identify risk factors of mortality. Results of the analysis were presented as hazard ratios (HRs) and 95% confidence intervals (CIs). Differences with an associated P value < 0.05 were considered statistically significant. All calculations were performed using JMP Pro 14 (SAS Institute, Tokyo, Japan).

Results

Patient characteristics. A total of 23 PH patients (mean PA pressure, 44 [32–50] mmHg) with 30 SVTs were enrolled; 19 with pulmonary arterial hypertension (PAH), 3 with chronic thromboembolic PH (CTEPH), and 1 with hemodialysis (Fig. 1). Table 1 shows the baseline characteristics of our cohort. There were 15 females and 8 males with a median age of 47 (35–60) years. The PAH included 13 patients with congenital heart disease (CHD), including atrial septal defect (ASD), ventricular septal defect (VSD), tetralogy of Fallot (TOF), atrioventricular septal defect (AVSD) and anomalous pulmonary venous return. Twelve of 13 patients with CHD had prior cardiac surgical intervention, 2 patients (numbers 10 and 16) had previously received a pacemaker for sick sinus syndrome, and none of CTEPH patients had inferior vena cava filters (Data Supplement and Supplemental Table 1).

Electrophysiological study and ablation. Supplemental Table 2 shows the characteristics of the procedures. At the time of the first procedure, the arrhythmia diagnoses were AFL in 18, IART in 5, FAT in 3, and AVNRT in 1 patient. Multiple distinct atrial arrhythmias were present in 4 patients (for example, AFL and IART or FAT; Supplemental Table 2). CHD was present in 10 of 18 patients with AFL, and in 6 of 8 patients with AT. Representative cases with AFL and AT are illustrated in Supplemental Figures. 1 and 2, respectively. At the first procedure, cavo tricuspid isthmus (CTI) ablation was performed in 18 patients, AT ablation in 10 patients, and
Figure 1. Study population and diagnosis. AFL: atrial flutter, AT: atrial tachycardia, AVNRT: atrioventricular nodal reentrant tachycardia, CRF: chronic renal failure, CTEPH: chronic thromboembolic pulmonary hypertension, FAT: focal atrial tachycardia, IART: intra-atrial reentrant tachycardia, ns: non-sustained, PAH: pulmonary arterial hypertension.

Table 1. Baseline characteristics according to the presence or absence of SVT after the last RFCA procedure. AAD antiarrhythmic drug, AF: atrial fibrillation, AFL: common atrial flutter, AT: atrial tachycardia, AVNRT: atrioventricular nodal reentrant tachycardia, BNP: brain natriuretic peptide, CHD: congenital heart disease, CI: cardiac index, CO: cardiac output, CRF: chronic renal failure, CTEPH: chronic thromboembolic pulmonary hypertension, PAH: pulmonary arterial hypertension, PAP: pulmonary artery pressure, PCWP: pulmonary capillary wedge pressure, PG: prostaglandin, PVR: pulmonary vascular resistance, RAP: right atrium pressure, RFCA: radiofrequency catheter ablation, SvO₂: mixed venous oxygen saturation, SVT: supraventricular tachycardia. *AT did not include non-sustained AT in this table.
slow pathway ablation in 1 patient. The rate of complete success following a single procedure was 83% (19/23 patients) and the partial success rate was 17% (4/23 patients). The acute complete success rate following the first procedure was 87% (26/30 SVT): 94% (17/18) in patients with AFL, 72% (8/11) in patients with AT, and 100% (1/1) in a patient with AVNRT (Fig. 2). The partially successful procedures consisted of patients with AFL (n = 1) and unmappable non-sustained (ns) AT (n = 3).

Safety. The average procedure time was 195 (144–295) minutes (Supplemental Table 2). There was no associated heart failure, or requirement for intubation, inotropic therapy, or cardiac mechanical support. The only complication was bradycardia due to a junctional rhythm, which developed the same day of the procedure in a 22-year-old man who had successful ablation of persistent IART that sustained for 3.2 years (Case 2). Because of exacerbation of heart failure by junctional rhythm and sinus arrest that emerged after RFCA, a permanent pacemaker had been implanted after 8 days, resulting in improvement of the heart failure.

Short-term effectiveness of ablation. Twelve of 16 patients were able to decrease the number of AADs administered, and the number of AADs decreased from 1.1 to 0.5 drugs per patient after the first RFCA procedure (n = 23, p = 0.002, Fig. 3A). Serum BNP levels significantly improved when comparing pre-RFCA (sample before RFCA: 6 [4–13] days) levels to those after RFCA (sample after RFCA: 35 [25–58] days); there was a reduction from 231 pg/dl to 176 pg/dl (n = 17, p = 0.04, Fig. 3B). Although serum BNP levels decreased significantly in patients with completely successful RFCA (n = 14, p = 0.03, 204 pg/dl vs. 138 pg/dl), the levels did not reduce in patients with partially successful RFCA (n = 3, p = 0.98, 354 pg/dl vs. 353 pg/dl). Moreover, the average number of hospitalizations within 1 year before and after RFCA also decreased significantly from 0.6 to 0.1 episodes per patient (n = 22, p = 0.002, Fig. 3C).

Long-term follow-up. We performed a second procedure in 4 patients (in 3 patients due to recurrence of targeted SVT in the first procedure and in 1 patient due to the onset of new SVT), and a third procedure in 1 patient who had recurrence of targeted SVT in the second procedure; all procedures were a complete success in the end (Supplemental Table 2). During a median follow-up of 5.1 year (2.1–9.1) after the last procedure, SVTs occurred in 12 patients (9 AT and 3 AF), of which recurrence of the targeted SVT was seen in 2 patients (both with AT) and new onset of SVT was seen in the remaining 10 patients (7 AT and 3 AF; Supplemental Table 2). Rate control was performed with verapamil or digoxin in the 2 patients with symptomatic non-sustained AT.

There was no difference in the baseline characteristics between patients with and without any SVT after the last RFCA procedure (Table 1). Overall, there were 8 deaths among 23 patients during follow-up, including 6 patients due to worsening of right cardiac failure, 1 patient who experienced sudden death, and 1 patient who died of unknown cause. The 1-, 3-, 5-, and 10-year survival rates after the first procedure were 100%, 80%, 74%, and 43%, respectively (Supplemental Fig. 3A). In the long-term, Kaplan–Meier survival curves showed that patients with any SVT after the last RFCA had a lower survival rate compared to those without (p = 0.0297, Fig. 4). There was same trend for higher all-cause mortality with SVT after the last RFCA in only patients with
PAH, though the difference was not statistically significant ($p=0.10$, Supplemental Fig. 3B). Univariate analysis revealed that intravenous PGI2 and any SVT after last RFCA were significant risk factors for mortality (intravenous PGI2 HR 4.23, 95%CI 0.99–18.00, $p=0.047$; any SVT after last RFCA HR 5.19, 95%CI 1.01–26.65, $p=0.031$).

Multivariate analysis revealed that any SVT after last RFCA was an independent risk factor for mortality (HR 9.31, 95%CI 1.19–73.01, $p=0.016$, Table 2).

| Table 2. Cox regression analysis of risk factors for mortality. AAD antiarrhythmic drug, BNP: brain natriuretic peptide, CHD: congenital heart disease, CI: cardiac index, CO: cardiac output, PAP: pulmonary artery pressure, PCWP: pulmonary capillary wedge pressure, PG: prostaglandin, PVR: pulmonary vascular resistance, RAP: right atrium pressure, RFCA: radiofrequency catheter ablation, SvO2: mixed venous oxygen saturation, SVT: supraventricular tachycardia. |

|                      | Univariate analysis |                      | Multivariate analysis |
|----------------------|---------------------|----------------------|----------------------|
|                      | Hazard ratio (95% CI) | p value | Hazard ratio (95% CI) | p value |
| Age, yrs             | 0.99 (0.95–1.04)    | 0.71    | 1.02 (0.96–1.10)    | 0.51 |
| Sex, Female          | 2.14 (0.43–10.68)   | 0.32    | 4.13 (0.58–29.40)   | 0.12 |
| CHD                  | 0.82 (0.19–3.53)    | 0.79    |                      |      |
| Intravenous PGI2     | 4.23 (0.99–18.00)   | 0.047   | 5.10 (0.74–35.00)   | 0.07 |
| Number of AADs       | 1.49 (0.81–2.76)    | 0.19    |                      |      |
| BNP level, pg/mL     | 1.00 (0.99–1.01)    | 0.12    |                      |      |
| Hospitalizations     | 3.22 (0.66–23.46)   | 0.15    |                      |      |
| Mean PAP, mmHg       | 0.99 (0.93–1.04)    | 0.73    |                      |      |
| RAP, mmHg            | 0.98 (0.87–1.08)    | 0.67    |                      |      |
| CO, L/min            | 0.71 (0.35–1.42)    | 0.33    |                      |      |
| CI, L/min/m²         | 0.67 (0.24–1.58)    | 0.37    |                      |      |
| SvO₂, %              | 1.01 (0.96–1.09)    | 0.66    |                      |      |
| PCWP, mmHg           | 0.93 (0.82–1.06)    | 0.28    |                      |      |
| PVR, dyne·sec/cm⁵    | 1.00 (0.99–1.00)    | 0.89    |                      |      |
| Any SVT after last RFCA | 5.19 (1.01–26.65)   | 0.031   | 9.31 (1.19–73.01)   | 0.016 |

Figure 3. Acute success rate of radiofrequency catheter ablation for supraventricular tachycardia. AFL: atrial flutter, AT: atrial tachycardia, AVNRT: atrioventricular nodal reentrant tachycardia, FAT: focal atrial tachycardia, IART: intra-atrial reentrant tachycardia, ns: non-sustained.

PAH, though the difference was not statistically significant ($p=0.10$, Supplemental Fig. 3B). Univariate analysis revealed that intravenous PGI2 and any SVT after last RFCA were significant risk factors for mortality (intravenous PGI2 HR 4.23, 95%CI 0.99–18.00, $p=0.047$; any SVT after last RFCA HR 5.19, 95%CI 1.01–26.65, $p=0.031$). Multivariate analysis revealed that any SVT after last RFCA was an independent risk factor for mortality (HR 9.31, 95%CI 1.19–73.01, $p=0.016$, Table 2).
Discussion

Main findings. This study showed that (1) the RFCA procedure for SVT in patients with PH is successful and safe, and non-sustained and unmappable AT results in RFCA failure; (2) in the short-term, RFCA improves quality of life (QOL) such as decreasing the number of AADs taken, BNP levels, and the number of hospitalizations; and (3) several new-onset SVTs occur over the long-term, and overall prognosis is not good, especially in those where all SVTs were not eliminated. Our findings are particularly important because, to our knowledge, this is the first report to demonstrate that the any SVTs after RFCA are significantly associated to mortality in patients with PH during long-term follow-up after RFCA.

Safety. Catheter ablation of SVT in patients with PH might be challenging in clinical practice, because mortality following heart catheterization for PH has been reported to be high. A more recent study reported the mortality to be lower in a special facility for patients with PH. Warren et al. identified predictors of catheterization-related complications in the PH population. Their predictors included age < 2 years, use of general anesthesia, need for intervention, and mean right atrial pressure. Risk factors for morbidity and mortality in non-cardiac surgery may also be useful predictors. Although a patient with high right atrial pressure and mean PAP corresponded to general anesthesia in this study, none faced clinical deterioration as a result of RFCA. The frequency of complications associated with catheter ablation for SVT in non-PH patients is not high. In the few reports including small numbers of patients with PH, the complication rate of RFCA for SVT was 0–14% (Table 3). Bradfield et al. reported the exacerbation of right heart failure and death from lead dislodgement after AVNRT ablation to be potential complications. One patient in our study experienced bradycardia after RFCA for persistent IART of 3.2 years duration, and it was treated with permanent pacemaker for the alleviation of heart failure 8 days later, because the sudden onset of bradycardia may cause hemodynamic deterioration in patients with PAH. One should remain aware of sick sinus syndrome after RFCA in patients with PH as well as those with a long duration of SVT.

Short-term efficacy of RFCA. Our study population comprised of patients mostly with AAD-resistant symptomatic SVT. Recent guidelines recommend therapy for SVT with AADs without negative inotropic effects such as amiodarone, although amiodarone can interact with PAH-targeted therapies and may cause life-threatening thyroid dysfunction; furthermore, specific data regarding efficacy are lacking. In previous studies about RFCA for SVT in patients with PH, the acute success rate of RFCA for typical AFL was 86–100%, which is in accordance with our study results. Anatomical remodeling may increase RF lesions to obtain bidirectional isthmus block, but does not appear to have an impact on the acute success rate of RFCA for AFL. Compared with AFL, less research has been done on RFCA for AVNRT and AT in patients with PH. Tongers et al. reported the acute success rate of RFCA for AVNRT to be 100% in patients with PH, which is in accordance with our study results. Bandorski et al. reported the acute success rate of RFCA for AT.
in patients with PH to be 31% (4/13 patients). Although the success rate of IART was 100% (2/2), the success rate for other focal or non-focal ATs was only 18% (2/11) due to multifocal tachycardia, or inability to place the catheter into a dilated right atrium. On the other hand, our results showed a higher acute success rate of RFCA for AT at 73% (8/11; 5/11 IART and 3/3 FAT). The reason for failure was unmappable non-sustained ATs of unknown mechanism, and all the mappable ATs were successfully ablated in our study. Two reasons may explain these different results. First, the past study mainly included patients with PH associated with left-sided heart disease (42%) and multifocal complex substrates AT (57%) including the left atrium. Our study consisted of PH patients who underwent SVT ablation in only right atrium because hemodynamic deterioration after AF RFCA with pulmonary vein isolation has been reported in patients with PH. In addition, this study mainly included CHD-related PH patients (57%), although PH multicenter registry showed that there was no significant difference in prognosis between patients with idiopathic PAH and CHD. Second, the introduction of a 3D mapping system may have contributed to the success rate.

Bradfield et al. reported an improvement in serum BNP levels and systolic pulmonary arterial pressures after RFCA for AFL in patients with PH. Our research revealed that RFCA for SVT decreased not only the number of AADs administered and serum BNP levels, but also hospital admission due to heart failure within 1 year of RFCA.

Table 3. Previous literature about RFCA for SVT in patients with pulmonary hypertension. AFL: common atrial flutter, AT: atrial tachycardia, AVNRT: atrioventricular nodal reentrant tachycardia, ERS: European Respiratory Society, ESC: European Society of Cardiology, IART: intra-atrial reentrant tachycardia, PA: pulmonary arterial, PH: pulmonary hypertension, RFCA: radiofrequency catheter ablation, SD: standard deviation, SVT: supraventricular tachycardia.

| Author                 | ESC/ERS PH Clinical group | Mean PA pressure (mmHg) | Target SVT      | Success rate | Complications |
|------------------------|---------------------------|-------------------------|-----------------|--------------|---------------|
| Tongers et al.5        | 1, 4 (n = unknown)        | 50 ± 10                 | AVNRT: 3        | 100% (3/3)   | 0% (0/8)      |
|                        |                           |                         | AFL: 5          | 100% (5/5)   |               |
| Bradfield et al.6      | 1 (n = 11), 4 (n = 11)    | 99 ± 35                 | AFL: 12         | 86% (12/14)  | 14% (2/14)    |
|                        | 4 (n = 1) (systolic PA)   |                         | Right heart failure: 1 |               |               |
|                        |                           |                         | Death: 1        |               |               |
| Showkathali et al.18   | 1 (n = 11), 4 (n = 11)    | 54.5 ± 11.1             | AFL: 22         | 100% (22/22) | 0% (0/22)    |
| Laesebrink et al.21    | 1 (n = 3), 2 (n = 32), 4 (n = 3) | 36.3 ± 13.5 | AFL | 100% (38/38) | 0% (0/38)    |
| Bandorski et al.20     | 1 (n = 14), 2 (n = 23), 3 (n = 4), 4 (n = 8), 5 (n = 2), other (n = 4) | Unknown | AFL: 14 | 86% (12/14) |                |
|                        |                           |                         | AT: 11          | 18% (2/11)   |               |
|                        |                           |                         | IART: 2         | 100% (2/2)   |               |
|                        |                           |                         | AVNRT: 4        | 100% (4/4)   |               |

Long-term efficacy of RFCA. SVT in patients with PH may not only represent a simple marker of prognosis but may also be a cause of clinical deterioration. Recent prospective observational studies have suggested that male sex, older age, higher World Health Organization functional class (WHO FC), and lower SvO2 at baseline are strong predictors of worse survival in patients with PAH. Permanent AF is also reported to be an independent prognostic factor in patients with PH. In our study, patients with any SVT after the last RFCA procedure had similar baseline characteristics but a worse prognosis compared with those without. Patients with PH in our study had similar survival rates compared to those in a Japanese multicenter PH registry (3-year survival; 80% vs. 88%) and patients with PH without any SVT after RFCA had a higher survival rate compared to those with (3-year survival; 88% vs. 41%). This may indicate that treatment of SVT by RFCA could avoid clinical deterioration and improve the prognosis of patients with PH. Further prospective studies are needed to investigate whether the survival rate improves if all SVTs are eliminated by treatment such as prophylaxis with AADs, electric cardioversion, or RFCA.

Limitations
This study has few limitations. First, our study may have been subjected to selection bias because it was a single-center study, and indications for RFCA and hospitalization for SVT were based on the clinical situation of the patient and the judgment of specialists. Second, we included data from an old era before the use of current treatments. The survival rate in this study might be worse than the actual survival rate. Third, the association between SVT after ablation and mortality might not necessarily imply a causal relationship and this retrospective study did not exclude the possibility that the progression of the underlying PH disease itself caused long-term SVT and poor prognosis. Finally, the number of this study was relatively small and the study population was heterogeneous because PH is relatively rare. Information bias also could be an issue because of the missing data resulting from the retrospective nature of this study.
Conclusion

RFCA for SVT in patients with PH is a safe and effective therapy in the short-term, but recurrence of targeted and non-targeted SVT was common and associated with higher all-cause mortality in the long-term. Our data suggest that maintenance of a stable sinus rhythm after RFCA should be considered an important treatment goal in patients with PH.

Received: 8 April 2021; Accepted: 21 July 2021
Published online: 10 August 2021

References

1. Humbert, M., Sitbon, O. & Simonneau, G. Treatment of pulmonary arterial hypertension. N. Engl. J. Med. 351, 1425–1436 (2004).
2. Skoro-Sajer, N. et al. Surgical specimens, haemodynamics and long-term outcomes after pulmonary endarterectomy. Thorax 69, 116–122 (2014).
3. Humbert, M. et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur. Respir. J. 36, 549–555 (2010).
4. Benza, R. L. et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 142, 448–456 (2012).
5. Tongers, J. et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am. Heart J. 153, 127–132 (2007).
6. Bradfield, J. et al. Catheter ablation of typical atrial flutter in severe pulmonary hypertension. J. Cardiovasc. Electrophysiol. 23, 1185–1190 (2012).
7. Olsson, K. M., Nickel, N. P., Tongers, J. & Hoeper, M. M. Atrial flutter and fibrillation in patients with pulmonary hypertension. Int. J. Cardiol. 167, 2300–2305 (2013).
8. Wen, L. et al. Frequency of supraventricular arrhythmias in patients with idiopathic pulmonary arterial hypertension. Am. J. Cardiol. 114, 1420–1425 (2014).
9. Soon, E. et al. Risk of potentially life-threatening thyroid dysfunction due to amiodarone in idiopathic pulmonary arterial hypertension patients. J. Am. Coll. Cardiol. 57, 997–998 (2011).
10. Galie, N. et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT), Eur. Heart J. 37, 67–119 (2015).
11. Fuster, V. et al. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 70, 580–587 (1984).
12. Hoepfer, M. M. et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J. Am. Coll. Cardiol. 48, 2546–2552 (2006).
13. Zuckerman, W. A. et al. Safety of cardiac catheterization at a center specializing in the care of patients with pulmonary arterial hypertension. Pulm. Circ. 3, 831–839 (2013).
14. McGlothin, D., Ivascu, N. & Heerdt, P. M. Anesthesia and pulmonary hypertension. Prog. Cardiovasc. Dis. 55, 199–217 (2012).
15. Hindricks G. The Multicentre European Radiofrequency Survey (MERFS): Complications of radiofrequency catheter ablation of arrhythmias The Multicentre European Radiofrequency Survey (MERFS) investigators of the Working Group on Arrhythmias of the European Society of Cardiology. Eur. Heart J. 34, 1644–1653 (1993).
16. Showkathali, R. et al. Right atrial flutter isthmus ablation is feasible and results in acute clinical improvement in patients with persistent atrial flutter and severe pulmonary arterial hypertension. Int. J. Cardiol. 149, 279–280 (2011).
17. Luisebrink, U. et al. Ablation of typical atrial flutter in patients with pulmonary hypertension. Heart Lung Circ 21, 695–699 (2012).
18. Haddad, F., Doyle, R., Murphy, D. J. & Hunt, S. A. Right ventricular function in cardiovascular disease, part II: Pathophysiology, clinical importance, and management of right ventricular failure. Circulation 117, 1717–1731 (2008).
19. Sonug, C. et al. Predictors of sick sinus syndrome in patients after successful radiofrequency catheter ablation of atrial flutter. Yonsei Med. J. 56, 31–37 (2015).
20. Bandorski D, Schmitt J, Kurzelechner C, Erkapic D, Hamm CW, Seeger W, et al. Electrophysiological studies in patients with pulmonary hypertension: A retrospective investigation. Biomed. Res. Int. 2014, 617565 (2014).
21. Aznouridis, K., Hobson, N., Rigg, C. & Bragadeesh, T. Emergency percutaneous closure of an iatrogenic atrial septal defect causing right-to-left shunt and severe refractory hypoxemia after pulmonary vein isolation. JACC Cardiovasc. Interv. 8, e179–e181 (2015).
22. Kozu, K. et al. Current status of long-term prognosis among all subtypes of pulmonary hypertension in Japan. Int. J. Cardiol. 300, 228–235 (2020).
23. McGoon, M. D. et al. Pulmonary arterial hypertension: Epidemiology and registries. J. Am. Coll. Cardiol. 62, D51–59 (2013).
24. Nickel, N. et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 39, 589–596 (2012).
25. Tamura, Y. et al. Effectiveness and outcome of pulmonary arterial hypertension-specific therapy in Japanese patients with pulmonary arterial hypertension. Circ. J. 82, 275–282 (2017).

Acknowledgements

We would like to thank Editage (www.editage.com) for English language editing. This study was supported by JSPS KAKENHI grant number 19K17545, Tokyo, Japan.

Author contributions

Y.I. is the guarantor. H.K., J.K., Y.I., T.N. and K.S. designed the study. H.K., J.K. and Y.I. prepared the manuscript with input and critical feedback from all authors. H.K. and Y.I. analyzed the data. All authors critically reviewed and developed the final manuscript.

Competing interests

TK, KI and KY received honoraria for educational lectures from Biotronik. KM received research grants from Bristol-Myers Squibb, Pfizer, Takeda Science Foundation and Suzuken Memorial Foundation. TO received honoraria for educational lectures from Actelion, Nippon Shinyaku and Bayer, and research grants from Actelion,
Secom medical system, Nippon Shinyaku, Bayer, Mochida and Integrated development associates. KS received honoraria for educational lectures from Medtronic, Boehringer-Ingelheim, Abbott, Bayer, Japan Lifeline and Daiichi Sankyo, and research grants from Biotronik. KK received honoraria for educational lectures from Medtronic, Bayer, Daiichi-Sankyo and Bristol-Myers Squibb, and research grants from Medtronic, EPI and Boston Scientific. All other authors (HK, JK, YI, TN, NU, KN, MW, Tao, SN, Tai, KK) have no financial interests to declare.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-95508-3.

Correspondence and requests for materials should be addressed to Y.Y.I.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021